Related Experiment Video
Updated: Apr 21, 2026
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
Targeting multiple types of tumors using NKG2D-coated iron oxide nanoparticles
Ming-Ru Wu1, W James Cook, Tong Zhang
1Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
Abstract:
Iron oxide nanoparticles (IONPs) hold great potential for cancer therapy. Actively targeting IONPs to tumor cells can further increase therapeutic efficacy and decrease off-target side effects. To target tumor cells, a natural killer (NK) cell activating receptor, NKG2D, was utilized to develop pan-tumor targeting IONPs. NKG2D ligands are expressed on many tumor types and its ligands are not found on most normal tissues under steady state conditions. The data showed that mouse and human fragment crystallizable (Fc)-fusion NKG2D (Fc-NKG2D) coated IONPs (NKG2D/NPs) can target multiple NKG2D ligand positive tumor types in vitro in a dose dependent manner by magnetic cell sorting. Tumor targeting effect was robust even under a very low tumor cell to normal cell ratio and targeting efficiency correlated with NKG2D ligand expression level on tumor cells. Furthermore, the magnetic separation platform utilized to test NKG2D/NP specificity has the potential to be developed into high throughput screening strategies to identify ideal fusion proteins or antibodies for targeting IONPs. In conclusion, NKG2D/NPs can be used to target multiple tumor types and magnetic separation platform can facilitate the proof-of-concept phase of tumor targeting IONP development.
Insights
Iron oxide nanoparticles (IONPs) targeting cancer cells show promise for therapy. Researchers developed NKG2D-coated IONPs that effectively target various tumor types, enhancing cancer treatment potential.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Iron oxide nanoparticles (IONPs) offer significant potential for cancer therapy.
- Enhancing IONP targeting to tumor cells can improve therapeutic outcomes and reduce side effects.
Purpose of the Study:
- To develop pan-tumor targeting IONPs using the natural killer (NK) cell activating receptor, NKG2D.
- To evaluate the efficacy of NKG2D-coated IONPs (NKG2D/NPs) in targeting tumor cells.
Main Methods:
- Developed fragment crystallizable (Fc)-fusion NKG2D coated IONPs (NKG2D/NPs).
- Utilized magnetic cell sorting to assess in vitro targeting of NKG2D ligand-positive tumor cells.
- Evaluated targeting under varying tumor cell to normal cell ratios.
Main Results:
- NKG2D/NPs demonstrated dose-dependent targeting of multiple tumor types in vitro.
- Effective tumor targeting was observed even at low tumor cell to normal cell ratios.
- Targeting efficiency correlated with NKG2D ligand expression levels on tumor cells.
Conclusions:
- NKG2D/NPs represent a viable strategy for targeting multiple cancer types.
- The magnetic separation platform facilitates the development and screening of targeted IONPs for cancer therapy.
